Targeting ADAR1 p150 triggers tumor inhibition and antitumor immunity to overcome immunotherapy resistance
Zhichao(Eric) Ai, Yuying Bian, Gang Li, Xiaobin S Wang, Sining Zhu, Yumeng Li, Xiangyu Yao, Zhipeng Yan · 2026
Read Targeting ADAR1 p150 triggers tumor inhibition and antitumor immunity to overcome immunotherapy resistance by Zhichao(Eric) Ai, Yuying Bian, Gang Li, Xiaobin S Wang, Sining Zhu, Yumeng Li, Xiangyu Yao, Zhipeng Yan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13217884.txt.
Description
Eight researchers report a new way to attack tumors that resist immune therapy, in work published in 2026. Many cancers learn to hide from the immune system, so standard immune drugs stop working. The team focused on a protein called ADAR1, which helps tumors stay hidden. A full block of this protein is risky, since one of its forms is needed by healthy cells.
The team found that a second form of the protein, called p150, is often high in human cancers and links to weak immune response. Removing that form slowed tumor growth and woke up an alarm signal that drew immune attack. A small part of the form, the Z-alpha domain, proved to be the key weak point. Blocking just that part copied the full effect, which points to a safer drug target.
Catalog record
| CREATOR | Zhichao(Eric) Ai, Yuying Bian, Gang Li, Xiaobin S Wang, Sining Zhu, Yumeng Li, Xiangyu Yao, Zhipeng Yan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 57 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |